ArticleFrontiers in nutrition2025
Triglyceride glucose-body mass index is associated with diabetic kidney disease in type 2 diabetes mellitus patients without non-alcoholic fatty liver disease.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Different association between triglyceride-glucose index and mild cognitive impairment in type 2 diabetes mellitus patients with and without diabetic kidney disease.Frontiers in nutrition · 2025Article
- Diagnostic efficacy of remnant cholesterol inflammatory index in diabetic kidney disease: machine learning approaches.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: The triglyceride glucose-body mass index (TyG-BMI) is correlated not only to the onset of diabetic kidney disease (DKD) associated with nutrition (including glucose and triglyceride) metabolism but also incorporates body mass index (BMI), potentially serving as an indicator of non-alcoholic fatty liver disease (NAFLD). But, the links between TyG-BMI and DKD in individuals with and without NAFLD remains further exploration. Therefore, this present research aims to investigate the relationship between TyG-BMI and DKD in these patient groups and to evaluate its diagnostic value for DKD. Methods: A total of 425 individuals diagnosed with type 2 diabetes mellitus (T2DM) were categorized into the DKD group or the Control group. Clinical indicators were compared in these two groups, and the relationships between TyG-BMI and either the estimated glomerular filtration rate (eGFR) or the urinary albumin-to-creatinine ratio (UACR) were examined. Risk factors for DKD were examined, and the diagnostic value of TyG-BMI was assessed in patients without and with NAFLD. Results: Compared to 288 participants without DKD, 137 individuals with DKD exhibited higher TyG-BMI levels. In all individuals with T2DM, a higher TyG-BMI was recognized as a contributing factor to the development of DKD. Notably, this association was observed in patients without NAFLD, while no such link was established in those diagnosed with NAFLD. For T2DM patients lacking NAFLD, the TyG-BMI threshold of 49.2415 demonstrated a sensitivity of 91.3% and a specificity of 70.1%. Conclusion: Increased TyG-BMI values are associated with a higher risk of DKD and could act as potential indicators of DKD in individuals with T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.